This post was originally published on this sitehttps://i-invdn-com.akamaized.net/news/LYNXMPEB2M05R_M.jpg
Biogen announced earnings per share of $10.26 on revenue of $3.68B. Analysts polled by Investing.com anticipated EPS of $8.03 on revenue of $3.44B.
Biogen shares are down 5% from the beginning of the year , still down 25.28% from its 52 week high of $374.99 set on February 5. They are under-performing the Nasdaq 100 which is up 24.05% from the start of the year.
Biogen’s report follows an earnings beat by J&J on July 16, who reported EPS of $1.67 on revenue of $18.34B, compared to forecasts EPS of $1.49 on revenue of $17.61B.
Novartis ADR had beat expectations on Tuesday with second quarter EPS of $1.36 on revenue of $11.35B, compared to forecast for EPS of $1.34 on revenue of $11.9B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar